Published in Cancer Weekly, January 21st, 2003
The panel recommendation does not impact on the current use and approval of Casodex 50 mg formulation.
Although the advisory committee could not reach a consensus on the interpretation of the data and how the results from the trials apply specifically to U.S. patients, the committee did agree that the data appears to show Casodex 150 mg is a viable treatment option for patients in other regions...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.